Akari Therapeutics Adjusts ADS Ratio to Meet Nasdaq Listing Requirements
Event summary
- Akari Therapeutics will change its ADS-to-ordinary-share ratio from 1:2,000 to 1:80,000, effective March 31, 2026.
- The adjustment aims to maintain compliance with Nasdaq's minimum bid price requirement for continued listing.
- ADS holders will exchange 40 existing ADSs for 1 new ADS, with fractional shares sold and proceeds distributed.
- No changes to underlying ordinary shares or Nasdaq trading symbol (AKTX).
The big picture
Akari's ADS ratio adjustment reflects a common strategy among small-cap biotechs to maintain exchange listing compliance amid volatile stock prices. The move comes as the company advances its novel ADC pipeline, targeting RNA splicing for oncology applications. Success in meeting Nasdaq requirements will be critical as Akari seeks to attract investors ahead of potential clinical milestones.
What we're watching
- Market Reaction
- How the ADS ratio change will impact investor sentiment and trading activity.
- Compliance Sustainability
- Whether the adjusted ratio will ensure long-term compliance with Nasdaq's listing standards.
- Clinical Progress
- The pace at which Akari advances its lead candidate, AKTX-101, toward First-In-Human trials.
Related topics